Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 October 2020 | Story Leonie Bolleurs | Photo Supplied
Prof Edilegnaw Wale Zegeye, who has joined the UFS Department of Agricultural Economics, believes university education is not just a requirement for learners to receive a certificate; it is a means to change their character, capacity, and reasoning.

Edilegnaw Wale Zegeye joined the Department of Agricultural Economics at the University of the Free State (UFS) as Professor of Agricultural Development Economics and Policy on 1 October 2020.

True to his belief that life is like riding a bicycle – to keep your balance, you must keep moving (Albert Einstein) – Prof Zegeye is not planning to wait for life to happen. He says that he is looking forward to engaging with his colleagues in the department regarding new challenges in the areas of teaching, research, and community engagement.

Teaching and learning

Prof Zegeye believes COVID-19 has made it necessary to come up with new ways and means of realising effective teaching and learning. He is convinced that even though online teaching has suddenly become the norm, many universities, including the UFS, will in future have to adopt some form of a hybrid, merging online with contact classes. 

“Given the uncharted territories we have to navigate, I foresee operational and content-related challenges in this area,” he says. 

These challenges, he believes, will require disrupting the status quo courageously, without neglecting the implications for teaching and learning outcomes.

Prof Zegeye is of the opinion that university education is not just a requirement for learners to receive a certificate. “It is a means to change their character, capacity, and reasoning. It is not about learning facts but enabling learners to think critically.”

His goal for his students is to enable them to master the subject matter content, not just memorise lecture notes to pass examinations. “Students should not expect everything from us, as teaching and learning is a two-way process. It is not a transfer of knowledge from a lecturer to students,” he says.

According to Prof Zegeye, success in teaching and learning is the outcome of the collective engagement of the lecturer, students, and the subject matter. He believes that was why Benjamin Franklin once said: “Tell me and I forget. Teach me and I remember. Involve me and I learn.”

Research

“In relation to research, the biggest challenge I anticipate is in terms of linking evidence-based knowledge with policy, implementation, and impact on the ground.”

He says the biggest challenge was to ensure that the knowledge generated is taken up by the relevant organisations and authorities in order to address the development-policy problem being examined. “This would, among other things, call for fixing the knowledge-action gap, addressing conflicts of interest, and engaging all the relevant stakeholders along, what I would call, the Research-Knowledge-Policy-Impact Nexus,” says Prof Zegeye. 

Prof Zegeye has more than twenty years of experience with higher education institutions, including the positions of Senior Lecturer, Associate Professor, Professor, and Honorary Professor (current appointment) in Agricultural Economics at the University of KwaZulu-Natal (UKZN). 

Although he spent several years at UKZN, he started his academic career at Alemaya University in Ethiopia. It was also at this university that he received a BSc in Agricultural Economics. He continued with his studies and obtained a master’s degree in Agricultural Development Economics from Wageningen University (the Netherlands), and later a doctoral degree in Agricultural and Natural Resources Economics from the University of Bonn. He obtained all degrees with distinction. 

Prof Zegeye has also gained valuable experience from working as an economist on the Genetic Resources Policy Initiative (GRPI) project of Bioversity International in Kenya. He has also been a consultant to, among others, the International Food Policy Research Institute and the International Livestock Research Institute. 

“Building on my experiences, I strongly believe that there is always room for improvement in whatever we do. If we all agree with that philosophy, all of us have a unique contribution to make to achieve excellence in what we do. There is a need to remind ourselves that excellence is not a destination; it is a journey that all of us need to take as a collective responsibility,” states Prof Zegeye. 

Published articles

To date, he has published more than 80 papers on water use in smallholder agriculture, agrobiodiversity conservation and technology adoption on smallholder farms, agricultural development policy, and impact assessment of development projects/programmes/policies. Prof Zegeye is also associate editor of the International Journal of Climate Change Strategies and Management and serves as a reviewer for various internationally accredited journals.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept